Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


03.12.2018

2 Biochemistry (Mosc)
1 Brain Res
2 J Biol Chem
1 J Neurochem
8 Mov Disord
2 Neurobiol Dis
4 Neurology
1 Neuropsychology
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Biochemistry (Mosc)

  1. LEBEDEVA OS, Lagarkova MA
    Pluripotent Stem Cells for Modelling and Cell Therapy of Parkinson's Disease.
    Biochemistry (Mosc). 2018;83:1046-1056.
    PubMed     Text format     Abstract available

  2. SIMONOVA VV, Vetchinova AS, Novosadova EV, Khaspekov LG, et al
    Genome Editing and the Problem of Tetraploidy in Cell Modeling of the Genetic Form of Parkinsonism.
    Biochemistry (Mosc). 2018;83:1040-1045.
    PubMed     Text format     Abstract available


    Brain Res

  3. LIU XG, Lu S, Liu DQ, Zhang L, et al
    ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson's and Huntington's diseases.
    Brain Res. 2018 Nov 24. pii: S0006-8993(18)30600.
    PubMed     Text format     Abstract available


    J Biol Chem

  4. YAMASAKI TR, Holmes BB, Furman JL, Dhavale DD, et al
    Parkinson's disease and multiple system atrophy have distinct alpha-synuclein seed characteristics.
    J Biol Chem. 2018 Nov 26. pii: RA118.004471. doi: 10.1074/jbc.RA118.004471.
    PubMed     Text format     Abstract available

  5. FLYNN JD, McGlinchey RP, Walker RL 3rd, Lee JC, et al
    Structural features of alpha-synuclein amyloid fibrils revealed by Raman spectroscopy.
    J Biol Chem. 2018;293:767-776.
    PubMed     Text format     Abstract available


    J Neurochem

  6. CILENTO EM, Jin L, Stewart T, Shi M, et al
    Mass Spectrometry: A Platform for Biomarker Discovery and Validation for Alzheimer's and Parkinson's Diseases.
    J Neurochem. 2018 Nov 26. doi: 10.1111/jnc.14635.
    PubMed     Text format     Abstract available


    Mov Disord

  7. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mov Disord. 2018 Nov 23. doi: 10.1002/mds.27492.
    PubMed     Text format     Abstract available

  8. KRISTIANSEN M, Maple-Grodem J, Alves G, Arepalli S, et al
    A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27555.
    PubMed     Text format    

  9. JANKOVIC J
    Pathogenesis-targeted therapeutic strategies in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27534.
    PubMed     Text format    

  10. IRMEN F, Horn A, Meder D, Neumann WJ, et al
    Sensorimotor subthalamic stimulation restores risk-reward trade-off in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27576.
    PubMed     Text format     Abstract available

  11. CUI SS, Du JJ, Liu SH, Meng J, et al
    Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27569.
    PubMed     Text format     Abstract available

  12. DE SOUZA CP, Dos Santos MGG, Hamani C, Fonoff ET, et al
    Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1828-1829.
    PubMed     Text format    

  13. MEADOWS SM, Conti MM, Gross L, Chambers NE, et al
    Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Mov Disord. 2018;33:1740-1749.
    PubMed     Text format     Abstract available

  14. SAMOTUS O, Jog M
    Reply to: Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1829-1830.
    PubMed     Text format    


    Neurobiol Dis

  15. HUANG YR, Xie XX, Ji M, Yu XL, et al
    Naturally occurring autoantibodies against alpha-synuclein rescues memory and motor deficits and attenuates alpha-synuclein pathology in mouse model of Parkinson's disease.
    Neurobiol Dis. 2018 Nov 24. pii: S0969-9961(18)30401.
    PubMed     Text format     Abstract available

  16. CHO SS, Christopher L, Koshimori Y, Li C, et al
    Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway.
    Neurobiol Dis. 2018;124:176-182.
    PubMed     Text format     Abstract available


    Neurology

  17. GANESH A, Galetta S
    Editors' note: Demoralization in Parkinson disease.
    Neurology. 2018;91:1029.
    PubMed     Text format    

  18. BRUNO V, Mancini D, Zurowski M, Miyasaki JM, et al
    Reader response: Demoralization in Parkinson disease.
    Neurology. 2018;91:1029.
    PubMed     Text format    

  19. KOO BB
    Author response: Demoralization in Parkinson disease.
    Neurology. 2018;91:1030.
    PubMed     Text format    

  20. KARCESKI S
    Parkinson disease and mortality: Understanding how the two are connected.
    Neurology. 2018;91:e2106-e2108.
    PubMed     Text format    


    Neuropsychology

  21. SUNDARAM S, Muller-Oehring EM, Fama R, Bronte-Stewart HM, et al
    Information processing deficit in older adults with HIV infection: A comparison with Parkinson's disease.
    Neuropsychology. 2018 Nov 26. pii: 2018-57915-001. doi: 10.1037/neu0000500.
    PubMed     Text format     Abstract available


    PLoS One

  22. OUERFELLI-ETHIER J, Elsaeid B, Desgroseilliers J, Munoz DP, et al
    Anti-saccades predict cognitive functions in older adults and patients with Parkinson's disease.
    PLoS One. 2018;13:e0207589.
    PubMed     Text format     Abstract available

  23. CANTU H, Cote JN, Nantel J
    A new method based on quiet stance baseline is more effective in identifying freezing in Parkinson's disease.
    PLoS One. 2018;13:e0207945.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: